COVID-19 vaccine doses

[Photo from Pexels]

The mRNA technology company Moderna (Nasdaq:MRNA) said it is planning to charge between $110 to $130 for COVID-19 vaccine doses in the U.S. once private market sales begin.

Pfizer (NYSE:PFE) had previously announced that it was targeting the same range for COVID-19 vaccine doses.

Moderna CEO Stéphane Bancel said the company is now in discussions with hospitals, pharmacies and pharmacy benefit managers over plans to provide COVID-19 vaccine boosters.

Both Pfizer and Moderna plan to offer new variant-matched vaccine boosters this fall.

Falling demand, increased prices

While demand for COVID-19 vaccines has steeply declined over the past year, Moderna and Pfizer have made billions of dollars from the products in recent years. The two companies have jointly sold 1.2 billion doses of COVID-19 vaccines at a weighted average price of $20.69 per dose, according to KFF.

Ini…

[Photo from Pexels]

The mRNA technology company Moderna (Nasdaq:MRNA) said it is planning to charge between $110 to $130 for COVID-19 vaccine doses in the U.S. once private market sales begin.

Pfizer (NYSE:PFE) had previously announced that it was targeting the same range for COVID-19 vaccine doses.

Moderna CEO Stéphane Bancel said the company is now in discussions with hospitals, pharmacies and pharmacy benefit managers over plans to provide COVID-19 vaccine boosters.

Both Pfizer and Moderna plan to offer new variant-matched vaccine boosters this fall.

Falling demand, increased prices

While demand for COVID-19 vaccines has steeply declined over the past year, Moderna and Pfizer have made billions of dollars from the products in recent years. The two companies have jointly sold 1.2 billion doses of COVID-19 vaccines at a weighted average price of $20.69 per dose, according to KFF.

Ini…

Doses of the COVID-19 vaccine at Walter Reed National Military Medical Center, Bethesda, Md. [DoD photo by Lisa Ferdinando.]

A study of essential and frontline workers infected with COVID-19 found that recent vaccination was associated with a variety of benefits. In particular, the workers who had received two or three mRNA COVID-19 vaccine doses had lower viral loads than the unvaccinated. They also had fewer fever and chill symptoms and were less likely to require medical care.

Published in JAMA, the study involved 1,199 participants from Arizona, Florida, Minnesota, Oregon, Texas and Utah. Volunteers were subjected to weekly nasal swabs regardless of symptoms from December 14, 2020, to April 19, 2022. The median age of participants was 41.

The study period encompassed both the delta and omicron waves in the U.S.

The delta variant was more likely to be symptomatic. Only 3.9% of those infected wit…